Shareholders approve merger of BioAlliance Pharma and Topotarget

Published: 1-Jul-2014
Finance Pharmaceutical

The combined business will be renamed Onxeo after completion of the transaction


BioAlliance Pharma, a French developer of drugs for orphan oncology diseases, is to merge with Denmark-based biopharmaceutical company Topotarget after receiving shareholder approval for the deal.

The combined business aims to become a leading orphan oncology company and will be renamed Onxeo after completion.

No financial details have been revealed.

The shareholders also approved the appointment of Orfacare Consulting, represented by Bo Jesper Hansen, and of Per Samuelsson, of Healthcap, as board members of Onxeo, effective as of the completion of the merger. As previously announced, Judith Greciet will be the CEO of Onxeo and Patrick Langlois the Chairman of the Board.

Completion is now subject to registration by the relevant French and Danish authorities, and should take place during July.

  • Companies:
  • BioAlliance Pharma
See more

You may also like

Research & Development

Merger of BioAlliance Pharma and Topotarget to create new company called Onxeo

Read more
Transaction is expected to be completed in July/August

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
  3. Sanofi Pasteur launches 5-in-1 combination vaccine in China New vaccine Pentaxim reduces number of infant injections from 12 to four
  4. Indian government bans three medicines owing to health risks Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
  5. Flexicon optimises Rossix’s small batch filling and capping process Rossix has optimised its batch filling and capping process by using a peristaltic filler of the PF series and a FlexFeed30 tabletop bottle handling and capping system from Flexicon Liquid Filling

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Research & Development

Merger of BioAlliance Pharma and Topotarget to create new company called Onxeo

Transaction is expected to be completed in July/August
Finance

BioAlliance Pharma to merge with Topotarget

The companies have a pipeline of orphan oncology drugs
Manufacturing

BioAlliance Pharma collaborates with Penn Pharma on development of Validive

BioAlliance Pharma entrusts the pharmaceutical development of Validive to Penn Pharma, including the production of phase III clinical batches and the commercial production
Research & Development

BioAlliance receives ANR funding

To develop new applications of its mucoadheasive Lauriad technology
Drug Delivery

Ondansetron RapidFilm gains European approval

Suitable for children and adults with swallowing difficulties
Sustainability

Building strong foundations for a resilient and planet-friendly future

Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
Sustainability

Dickson achieves ISO 14001 certification

ISO 14001 certification highlights a companies' long-term efforts to manage its environmental impact
Subscribe now